The clinical advice remains the same: speak with your prescriber about whether adjusting your dose or considering a different medication would be appropriate
CVS Caremark selected Wegovy as its preferred GLP-1 for weight loss effective July 1, 2025, removing Zepbound from these formulary types: [2] Standard Control Formulary Most common employer formulary Advanced Control Formulary More restrictive formulary with lower premiums Value Formulary Cost-focused formulary used by smaller employers Background: The Zepbound Class Action Lawsuits In September 2025, two class action lawsuits were filed by Zepbound patients against CVS Caremark: [3][8] (Sept
Retrieved from: Torrence, R
By simultaneously activating the GLP-1, GIP, and Glucagon receptors, this compound is currently the subject of intensive study regarding its potential impact on metabolic efficiency and energy regulation
This consultation covers medical history, weight loss goals, and health assessments, allowing us to create a customized plan that best fits your needs